Ikena Oncology News

Ikena Oncology | 10-Q: Quarterly report

May 13 16:35 ET

Ikena Oncology | ARS: Annual Report to Security Holders

Apr 26 16:41 ET

Ikena Oncology | DEFA14A: Others

Apr 26 16:37 ET

Ikena Oncology | DEF 14A: Definitive information statements

Apr 26 16:26 ET

Ikena Oncology | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mar 12 07:52 ET

Ikena Oncology | 10-K: Annual report

Mar 12 07:32 ET

Ikena Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(2.771%),Abigail P. Johnson(2.771%)

Mar 11 08:22 ET

Ikena Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Germa Caroline

Mar 5 16:09 ET

Ikena Oncology | 3: Initial statement of beneficial ownership of securities-Officer Germa Caroline

Mar 5 16:05 ET

Ikena Oncology | 8-K: Current report

Feb 21 16:39 ET

Ikena Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Kenneth Griffin(0.4%),Citadel Advisors LLC(0.3%), etc.

Feb 14 17:02 ET

Ikena Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

Feb 14 16:56 ET

Ikena Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BVF Partners L.P.(9.9%),BVF Inc.(9.9%), etc.

Feb 14 09:52 ET

Ikena Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(9.545%),Abigail P. Johnson(9.545%)

Feb 9 09:21 ET

Ikena Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Ecsedy Jeffrey

Feb 2 17:17 ET

Ikena Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Manfredi Mark

Feb 2 17:13 ET

Ikena Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Marango Jotin

Feb 2 17:13 ET

Ikena Oncology | 8-K: Current report

Jan 18 00:00 ET

Ikena Oncology: Q3 2023 Earnings Report

Nov 9, 2023 07:30 ET

Ikena Oncology | 8-K: Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Nov 9, 2023 07:09 ET